A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Launched by MERUS N.V. · Jul 3, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called petosemtamab for patients with head and neck squamous cell carcinoma (HNSCC) who have already received other treatments. It aims to find out if petosemtamab is more effective than the treatment chosen by the doctor for patients whose cancer has returned or spread and cannot be cured with standard therapies. The trial is open to adults aged 18 and older who have been diagnosed with advanced HNSCC and have shown that their cancer progressed after receiving previous treatments, including certain immunotherapy and chemotherapy.
To participate, patients need to have measurable cancer that can be assessed by imaging tests and meet specific health criteria, such as not having serious ongoing illnesses or complications from past cancer treatments. Participants will receive either petosemtamab or the doctor's choice of treatment and will be monitored throughout the study. This trial is currently recruiting new participants, and it's important for anyone interested to discuss with their healthcare provider to see if they qualify and to understand what taking part might involve.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed ICF before initiation of any study procedures.
- • Age ≥ 18 years at signing of ICF.
- • Histologically previously confirmed HNSCC with evidence of metastatic or locally advanced disease not amenable to standard therapy with curative intent.
- • HNSCC patients progressed on or after anti-PD-1 therapy and platinum-containing therapy.
- • The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
- • Documentation of p16 status (positive or negative) by local laboratory IHC for patients with primary oropharyngeal cancer.
- • A baseline new tumor sample unless the patient has an available tumor sample as an FFPE block with sufficient material.
- • Measurable disease as defined by RECIST v1.1 by radiologic methods.
- • ECOG PS of 0 or 1
- • Life expectancy ≥ 12 weeks, as per investigator
- • Adequate organ function (as per protocol)
- Exclusion Criteria:
- • Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.
- • Known leptomeningeal involvement
- • Any systemic anticancer therapy within 4 weeks of the first dose of study treatment.
- • Major surgery or radiotherapy within 3 weeks of the first dose of study treatment.
- • Persistent Grade \>1 clinically significant toxicities related to prior antineoplastic therapies
- • History of hypersensitivity reaction to any of the excipients of treatment required for this study.
- • Unstable angina; history of congestive heart failure of Class II-IV New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment or history of myocardial infarction within 6 months of study entry
- • History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease
- • Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy
- • Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders
- • Patients with known infectious diseases (as per protocol)
- • Pregnant or breastfeeding patients
- • Patient has a primary tumor site of nasopharynx (any histology).
About Merus N.V.
Merus N.V. is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapeutic solutions for patients with cancer. Utilizing its proprietary antibody technology platform, Merus specializes in the development of bispecific antibodies designed to target multiple pathways in tumor biology, enhancing efficacy while minimizing toxicities. With a robust pipeline of drug candidates undergoing various stages of clinical trials, Merus is committed to addressing unmet medical needs in oncology and improving patient outcomes through cutting-edge science and strategic partnerships. The company is headquartered in Utrecht, Netherlands, and focuses on translating groundbreaking research into meaningful therapies for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
Louisville, Kentucky, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Spokane, Washington, United States
Darlinghurst, , Australia
Jerusalem, , Israel
Tel Aviv, , Israel
Bradenton, Florida, United States
Orlando, Florida, United States
Saint Louis, Missouri, United States
Albuquerque, New Mexico, United States
Blacksburg, Virginia, United States
Saint Leonards, , Australia
Providencia, , Chile
Tel Hashomer, , Israel
Goyang Si, , Korea, Republic Of
Kaohsiung, , Taiwan
New York, New York, United States
Cincinnati, Ohio, United States
Charlottesville, Virginia, United States
Recoleta, , Chile
Santiago, , Chile
Haifa, , Israel
La Jolla, California, United States
Palo Alto, California, United States
Portland, Oregon, United States
Nedlands, Western Australia, Australia
Santiago, , Chile
Hwasun, Jeollanam Do, Korea, Republic Of
Indianapolis, Indiana, United States
Columbus, Ohio, United States
El Paso, Texas, United States
Buenos Aires, , Argentina
Seoul, , Korea, Republic Of
Soeul, , Korea, Republic Of
Taipei City, , Taiwan
Baton Rouge, Louisiana, United States
Córdoba, , Argentina
Melbourne, , Australia
Changhua, , Taiwan
Taipei, , Taiwan
Liverpool, , United Kingdom
London, , United Kingdom
Sutton, , United Kingdom
San Francisco, California, United States
Maple Grove, Minnesota, United States
Charleston, South Carolina, United States
Houston, Texas, United States
Seoul, , Korea, Republic Of
Taoyuan City, , Taiwan
Manchester, , United Kingdom
Taichung, , Taiwan
Chicago, Illinois, United States
Chattanooga, Tennessee, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
Nashville, Tennessee, United States
Denison, Texas, United States
Capital Federal, , Argentina
Viedma, , Argentina
Brussel, , Belgium
Namur, , Belgium
Greifswald, , Germany
Nijmegen, , Netherlands
Utrecht, , Netherlands
Madrid, , Spain
Pamplona, , Spain
Pamplona, , Spain
Cambridge, , United Kingdom
Middlesex, , United Kingdom
Madrid, , Spain
Valencia, , Spain
Duarte, California, United States
La Jolla, California, United States
Fort Myers, Florida, United States
Boston, Massachusetts, United States
Ciudad Autonoma De Buenos Aires, , Argentina
Darlinghurst, , Australia
Sydney, , Australia
Leuven, , Belgium
Recoleta, , Chile
Santiago, , Chile
Gießen, , Germany
Hamburg, , Germany
Thessaloníki, , Greece
Jerusalem, , Israel
Tel Aviv, , Israel
Milano, , Italy
Rozzano, , Italy
Amsterdam, , Netherlands
Barcelona, , Spain
Taipei, , Taiwan
Hackensack, New Jersey, United States
Cleveland, Ohio, United States
Caba, , Argentina
Nedlands, , Australia
Gent, , Belgium
Hamburg, , Germany
Athens, , Greece
Brescia, , Italy
Napoli, , Italy
Hwasun, , Korea, Republic Of
London, , United Kingdom
Prescott, Arizona, United States
Washington, District Of Columbia, United States
New Orleans, Louisiana, United States
Ann Arbor, Michigan, United States
Chapel Hill, North Carolina, United States
Pearland, Texas, United States
Rosario, , Argentina
Liège, , Belgium
Bordeaux, , France
Marseille, , France
Montpellier, , France
Paris, , France
Rouen, , France
Villejuif, , France
Aachen, , Germany
Hannover, , Germany
Leipzig, , Germany
Würzburg, , Germany
Athens, , Greece
Cuneo, , Italy
Gliwice, , Poland
Madrid, , Spain
Kaohsiung City, , Taiwan
Scottsdale, Arizona, United States
Sacramento, California, United States
Jacksonville, Florida, United States
Rochester, Minnesota, United States
Durham, North Carolina, United States
Brussels, , Belgium
Lyon, , France
Toulouse, , France
Berlin, , Germany
Heraklion, , Greece
Río, , Greece
Milano, , Italy
Skorzewo, , Poland
Lone Tree, Colorado, United States
Poitiers, , France
Chuo Ku, , Japan
Kashiwa, , Japan
Miki, , Japan
Sendai, , Japan
ōsaka Sayama, , Japan
Seoul, , Korea, Republic Of
Temple Terrace, Florida, United States
Rennes, , France
Vandœuvre Lès Nancy, , France
Nagoya, , Japan
Gdańsk, , Poland
London, , United Kingdom
Porto Alegre, , Brazil
Porto Alegre, , Brazil
Recife, , Brazil
Rio De Janeiro, , Brazil
São Paulo, , Brazil
São Paulo, , Brazil
Lille, , France
Chicago, Illinois, United States
Columbia, Maryland, United States
Bensalem, Pennsylvania, United States
Brasília, , Brazil
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported